Mesa Laboratories (MLAB) Competitors

$103.19
+1.39 (+1.37%)
(As of 04/26/2024 ET)

MLAB vs. SENS, VERV, PRME, ALLO, PROK, CVAC, MLYS, NUVB, NVAX, and GHRS

Should you be buying Mesa Laboratories stock or one of its competitors? The main competitors of Mesa Laboratories include Senseonics (SENS), Verve Therapeutics (VERV), Prime Medicine (PRME), Allogene Therapeutics (ALLO), ProKidney (PROK), CureVac (CVAC), Mineralys Therapeutics (MLYS), Nuvation Bio (NUVB), Novavax (NVAX), and GH Research (GHRS). These companies are all part of the "medical" sector.

Mesa Laboratories vs.

Mesa Laboratories (NASDAQ:MLAB) and Senseonics (NYSE:SENS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.

Mesa Laboratories has higher revenue and earnings than Senseonics. Senseonics is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesa Laboratories$219.08M2.54$930K$0.17607.04
Senseonics$22.39M9.86-$60.39M-$0.11-3.78

In the previous week, Mesa Laboratories and Mesa Laboratories both had 1 articles in the media. Mesa Laboratories' average media sentiment score of 1.00 beat Senseonics' score of 0.00 indicating that Mesa Laboratories is being referred to more favorably in the media.

Company Overall Sentiment
Mesa Laboratories Positive
Senseonics Neutral

90.6% of Mesa Laboratories shares are held by institutional investors. Comparatively, 12.4% of Senseonics shares are held by institutional investors. 5.2% of Mesa Laboratories shares are held by insiders. Comparatively, 3.9% of Senseonics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mesa Laboratories currently has a consensus target price of $130.00, indicating a potential upside of 25.98%. Senseonics has a consensus target price of $1.25, indicating a potential upside of 200.70%. Given Senseonics' higher possible upside, analysts clearly believe Senseonics is more favorable than Mesa Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesa Laboratories
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Senseonics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Mesa Laboratories received 216 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 63.82% of users gave Mesa Laboratories an outperform vote while only 25.00% of users gave Senseonics an outperform vote.

CompanyUnderperformOutperform
Mesa LaboratoriesOutperform Votes
217
63.82%
Underperform Votes
123
36.18%
SenseonicsOutperform Votes
1
25.00%
Underperform Votes
3
75.00%

Mesa Laboratories has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Senseonics has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Mesa Laboratories has a net margin of 0.45% compared to Senseonics' net margin of -270.13%. Mesa Laboratories' return on equity of 7.41% beat Senseonics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mesa Laboratories0.45% 7.41% 4.34%
Senseonics -270.13%-146.90%-49.81%

Summary

Mesa Laboratories beats Senseonics on 13 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLAB vs. The Competition

MetricMesa LaboratoriesProcess control instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$556.19M$20.84B$4.88B$7.55B
Dividend Yield0.63%1.01%2.91%3.95%
P/E Ratio607.0478.22232.4819.19
Price / Sales2.544.502,338.7085.76
Price / Cash8.5616.9447.0434.73
Price / Book1.403.204.764.33
Net Income$930,000.00$474.99M$103.54M$214.22M
7 Day Performance2.43%-0.35%0.74%1.88%
1 Month Performance-3.79%-8.81%-7.60%-5.23%
1 Year Performance-37.60%17.73%9.25%8.41%

Mesa Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SENS
Senseonics
0.4184 of 5 stars
$0.43
+7.5%
$1.25
+190.7%
N/A$228.25M$22.39M-3.91132
VERV
Verve Therapeutics
2.3427 of 5 stars
$6.88
-0.4%
$33.00
+379.7%
-60.9%$575.31M$11.76M-2.21255
PRME
Prime Medicine
2.8156 of 5 stars
$4.80
+0.4%
$16.89
+251.9%
N/A$575.71MN/A-2.21234Analyst Report
ALLO
Allogene Therapeutics
2.4498 of 5 stars
$3.37
-0.9%
$12.94
+283.9%
-45.7%$569.83M$90,000.00-1.61232Upcoming Earnings
Positive News
PROK
ProKidney
2.0169 of 5 stars
$2.53
-7.0%
$9.50
+275.5%
-78.3%$580.24MN/A-4.44163Short Interest ↓
News Coverage
CVAC
CureVac
3.9583 of 5 stars
$2.60
+2.8%
$15.00
+476.9%
-68.2%$582.09M$72.33M0.001,049Analyst Downgrade
Short Interest ↓
Analyst Revision
News Coverage
Gap Up
MLYS
Mineralys Therapeutics
1.385 of 5 stars
$11.43
+2.6%
$33.50
+193.1%
-9.3%$567.27MN/A-5.7228
NUVB
Nuvation Bio
3.2589 of 5 stars
$2.67
-0.4%
$6.60
+147.2%
+68.6%$582.19MN/A-7.8551Upcoming Earnings
NVAX
Novavax
3.7805 of 5 stars
$4.19
+2.9%
$17.00
+305.7%
-45.9%$586.39M$983.71M-0.761,543
GHRS
GH Research
1.2936 of 5 stars
$11.30
-3.6%
$39.50
+249.6%
+25.4%$587.94MN/A-16.6249Short Interest ↑
News Coverage

Related Companies and Tools

This page (NASDAQ:MLAB) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners